The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for SYD-101 (atropine sulfate) to slow the progression of myopia in children. Considered a common ...
Catalyst synthesis is the process of fabricating catalytic materials. It aims to optimize factors such as the catalyst activity, selectivity, stability and cost. Unlocking the potential of ...
The FDA has accepted the New Drug Application (NDA) submitted by Sydnexis for SYD-101, a low-dose atropine drop indicated for myopia management, with a Prescription Drug User Fee Act (PDUFA) target ...
Get article recommendations from ACS based on references in your Mendeley library. Pair your accounts.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback